We are live on ! Find out more
BRNS

Barinthus Biotherapeutics
BRNS

16 hedge funds and large institutions have $10.3M invested in Barinthus Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.08% more ownership

Funds ownership: 24.82% → 24.9% (+0.08%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less capital invested

Capital invested by funds: $10.7M → $10.3M (-$404K)

16% less funds holding

Funds holding: 19 → 16 (-3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
16
Holders Change
-3
Holders Change %
-15.79%
% of All Funds
0.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
1
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$8.38K
2
Millennium Management
Millennium Management
New York
+$945

Top Sellers

Rank Fund Capital Flow
1
BCM
BlueCrest Capital Management
Jersey
-$646K
2
Citadel Advisors
Citadel Advisors
Florida
-$34.1K
3
CCG
Catalina Capital Group
California
-$12K
4
BlackRock
BlackRock
New York
-$7.72K
5
IIM
Ipswich Investment Management
Massachusetts
-$5.82K
Name Holding Trade Value Shares
Change 		Change in
Stake
MGP
1
M&G plc
United Kingdom
$5.2M – – –
AI
2
Alphabet Inc
California
$1.83M – – –
HH
3
HSG Holding
Hong Kong
$1.39M – – –
DF
4
DC Funds
Virginia
$776K – – –
GS
5
Gilead Sciences
California
$749K +$722K +620,351 New
JHU
6
Johns Hopkins University
Maryland
$148K – – –
Baird Financial Group
7
Baird Financial Group
Wisconsin
$112K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$42.4K +$8.38K +7,200 +26%
IIM
9
Ipswich Investment Management
Massachusetts
$21.2K -$5.82K -5,000 -22%
Janney Montgomery Scott
10
Janney Montgomery Scott
Pennsylvania
$18K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$13.9K – – –
Millennium Management
12
Millennium Management
New York
$13.2K +$945 +812 +8%
CCG
13
Catalina Capital Group
California
$12.3K -$12K -10,296 -50%
Morgan Stanley
14
Morgan Stanley
New York
$9.69K -$4.61K -3,962 -33%
NECFA
15
New England Capital Financial Advisors
Connecticut
$126 – – –
RhumbLine Advisers
16
RhumbLine Advisers
Massachusetts
$72 – – –
BCM
17
BlueCrest Capital Management
Jersey
– -$646K -542,673 Closed
Citadel Advisors
18
Citadel Advisors
Florida
– -$34.1K -27,717 Closed
BlackRock
19
BlackRock
New York
– -$7.72K -6,485 Closed
UBS Group
20
UBS Group
Switzerland
– -$1.7K -1,432 Closed

BRNS Hedge Fund Activity: Q4 2024 in Review

16 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q4 2024, worth a combined $10.3M — down 3.8% from $10.7M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BRNS and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $8.38K. The largest seller was BlueCrest Capital Management, exiting entirely with an estimated $646K sold.

  • 16 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q4 2024, down from 19 in Q3 2024.
  • Funds reported $10.3M of Barinthus Biotherapeutics stock for Q4 2024, down 3.8% quarter-over-quarter.
  • 1 fund opened new Barinthus Biotherapeutics positions in Q4 2024 and 4 closed out, a net change of -3 holders.
  • The largest Barinthus Biotherapeutics buyer in Q4 2024 was Renaissance Technologies, an estimated $8.38K added.
  • The largest Barinthus Biotherapeutics seller in Q4 2024 was BlueCrest Capital Management, an estimated $646K sold.

Based on aggregated 13F filings for Q4 2024.